The global vasculitis drug market is projected to grow at a significant CAGR during the forecast period (2022-2028). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, in January 2022the European Commission approved Tavneos in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis, according to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). The approval is in line with expectations and follows the FDA's approval of Tavneos for the same indication in October 2021. Tavneos will be approved for sale in all European Union member states, as well as Iceland, Liechtenstein, and Norway.
Browse the full report description of “Global Vasculitis Drug Market Size, Share & Trends Analysis Report By Drug Class (Corticosteroids, Immunosuppressants, and Biologics), By Disease Type (Small Vessel, Large Vessel, and Medium Vessel Vasculitis) By End-User (Hospitals, Medical Clinics, Others), Forecast Period, 2022-2028” at https://www.omrglobal.com/industry-reports/vasculitis-drug-market
The EU approval is based on a comprehensive development programme that culminated in the results of the pivotal phase-III trial ADVOCATE, which compared treatment regimens including Tavneos to current standard of care treatment regimens with high dose glucocorticoid use in 331 patients with ANCA-associated vasculitis in 20 countries. The Birmingham Vasculitis Activity Score was used to determine whether the research fulfilled its primary goals of disease remission at week 26 and sustained remission at week 52. (BVAS). At week 52, Tavneos was found to be superior to the standard of care.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Drug Class
o By Disease Type
o By End-Use
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including GlaxoSmithKline plc, F. Hoffmann-La Roche AG, and Novartis International AG, among others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How does COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Vasculitis Drug Market Report Segment
By Drug Class
By End-Use
By Disease Type
Global Vasculitis Drug Market Report Segment by Region
North America
• The United States
• Canada
Europe
• The UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/vasculitis-drug-market